Paltusotine + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Syndrome
Conditions
Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
Trial Timeline
Nov 19, 2025 → Jan 1, 2030
NCT ID
NCT07087054About Paltusotine + Placebo
Paltusotine + Placebo is a phase 3 stage product being developed by Crinetics Pharmaceuticals for Carcinoid Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07087054. Target conditions include Carcinoid Syndrome, Carcinoid, Carcinoid Tumor.
What happened to similar drugs?
1 of 8 similar drugs in Carcinoid Syndrome were approved
Approved (1) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07087054 | Phase 3 | Recruiting |
| NCT05192382 | Phase 3 | Active |
| NCT04837040 | Phase 3 | Active |
| NCT03792555 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoid Syndrome